| Univariate analyses | Multivariate analyses | ||||
---|---|---|---|---|---|---|
P value | OR | 95% CI | P value | OR | 95% CI | |
Sex | 0.330 | 0.646 | 0.268–1.555 | — | — | — |
Age | 0.975 | 1.001 | 0.957–1.046 | — | — | — |
ECOG | 0.0499* | 0.507 | 0.241–1.065 | 0.046* | 0.159 | 0.026–0.970 |
 0–1 c |  |  |  |  |  |  |
 2 |  |  |  |  |  |  |
Tumor type | 0.795 | 1.018 | 0.892–1.161 | 0.770 | — | — |
TNM clinical classification | 0.508 | 0.786 | 0.385–1.605 | — | — | — |
Treatment line | 0.150 | 1.939 | 0.787–4.777 | 0.69 | 2.908 | 0.922–9.169 |
 First-line and second-line c |  |  |  |  |  |  |
 Third-line and above |  |  |  |  |  |  |
Treatment | 0.125 | 0.780 | 0.567–1.072 | 0.044* | — | — |
 Immunotherapy c |  |  |  | Base | — | — |
 Immunotherapy + targeted therapy |  |  |  | 0.005* | 0.156 | 0.045–0.544 |
 Immunotherapy + chemotherapy |  |  |  | 0.301 | 0.550 | 0.178–1.706 |
 Immunotherapy + chemotherapy + targeted therapy |  |  |  | 0.383 | 0.363 | 0.037–3.533 |
NLR | 0.0499* | 0.196 | 0.038–1.000 | 0.505 | 0.501 | 0.066–3.816 |
 Low (≤ 8.58) c |  |  |  |  |  |  |
 High (> 8.58) |  |  |  |  |  |  |
PLR | 0.091 | 0.492 | 0.216–1.120 | 0.216 | 0.537 | 0.200–1.440 |
 Low (< 180.68) c |  |  |  |  |  |  |
 High (≥ 180.68) |  |  |  |  |  |  |
AEC | 0.012* | 3.651 | 1.322–10.076 | 0.014* | 4.114 | 1.32–12.858 |
 Low (≤ 0.045 × 109/L) c |  |  |  |  |  |  |
 High (> 0.045 × 109/L) |  |  |  |  |  |  |